Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epeleuton in NAFLD
NCT02941549Phase 2Completed
- Sponsor
- Afimmune
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of epeleuton in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Afimmune. Primary endpoints: Change in Serum Alanine Aminotransferase at 16 weeks, Change in Liver Stiffness Measurements by Transient Elastography at 16 weeks and 1 more. Started Dec 2016; status: completed.
02
Drugs
epeleuton
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02941549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941549.